Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GT267-004 in CDAD
NCT00382304Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2006
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tolevamer potassium-sodium in Clostridioides difficile infection (CDI), sponsored by Sanofi. Primary endpoint: Extent of GT267-004 absorption. Started Sep 2006; status: completed.
02
Drugs
tolevamer potassium-sodium
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT00382304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382304.